Nucryst Pharmaceuticals Corp
			Symbol			NCS
			Shares Issued			18,325,365
			Close 2009-11-19			C$ 1.82
			Recent Sedar Documents

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Nucryst to hold special meeting Dec. 21

2009-11-20 18:29 ET - News Release

Mr. David Wills reports

NUCRYST ANNOUNCES SPECIAL MEETING OF SHAREHOLDERS

Nucryst Pharmaceuticals Corp. will hold a special meeting of shareholders on Monday, Dec. 21, 2009. The purpose of the meeting is to consider approval of two special resolutions. The first special resolution is to approve and authorize the sale of all or substantially all of the assets of Nucryst, substantially on the terms provided for in the asset purchase agreement dated Nov. 10, 2009, among Nucryst Pharmaceuticals Corp., Nucryst Pharmaceuticals Inc., Smith & Nephew Inc. and Smith & Nephew (Overseas) Limited.

If the first special resolution is approved, shareholders will be asked to consider a second special resolution approving the amalgamation of the corporation with 1499642 Alberta Ltd., a wholly owned subsidiary of the Westaim Corporation, substantially on the terms and conditions provided for in the amalgamation agreement dated Nov. 10, 2009, between Nucryst and 1499642 Alberta Ltd.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.